- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07694492
Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid
Determining the Feasibility of Utilizing a Medical-Legal Partnership Model to Reach Coal Miners Who Use Tobacco and Nicotine Products and Connect Them to a Pharmacy-based Cessation Program
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Background and rationale. Lung cancer rates are approximately 25% higher in Central Appalachia than in the rest of the U.S., and black-lung mortality has been markedly elevated in the region. Coal miners report the highest rates of cigarette smoking (about 23% vs. ~14% nationally) and smokeless tobacco use (about 23% vs. ~3% nationally) of any U.S. occupation, and TNP use magnifies the risk and severity of obstructive lung disease and lung cancer in this already high-risk group. National guidelines recommend that clinicians refer TNP users to cessation services via ask-advise-connect, but time constraints, limited provider buy-in, and patient factors limit adoption. In workers' compensation cases, claimants must prove their disease results from coal-dust exposure rather than TNP use, which creates both a health and a financial incentive for cessation and gives the miner-lawyer relationship unusual salience. This study leverages that relationship by having lawyers ask about TNP use (already routine at intake), advise quitting, and connect interested clients to a pharmacist-delivered cessation program (the novel component). QuitAid, previously developed and piloted by the study team, is a pharmacist-delivered MTM intervention designed to increase NRT adherence and promote cessation.
Aim 1 (implementation evaluation, lawyers). Guided by the Consolidated Framework for Implementation Research (CFIR), the team evaluates facilitators and barriers to adopting the ask-advise-connect model in approximately three black-lung law offices. Lawyers (up to 5 enrolled) complete baseline and follow-up surveys assessing self-efficacy, attitudes, and perceived facilitators/barriers, and participate in ~30-minute semi-structured telephone interviews (audio-recorded, analyzed thematically). Recruitment feasibility is measured by the proportion of coal miners referred per office and the number enrolled per month. Lawyers are study participants only, not investigators, and referral has no effect on a miner's legal case.
Aim 2 (randomized feasibility pilot, coal miners). Coal miners who use TNPs and have a current black-lung workers' compensation case with a participating law office are referred, screened, and consented by phone, complete a baseline assessment, and are then randomized 1:1 via computer-generated permuted-block randomization (generated in R, embedded in REDCap) to QuitAid (Yes vs. No). All participants receive 24 weeks of NRT beginning in Week 1 regardless of readiness to quit. Participants use of smoked TNPs (cigarettes, e-cigarettes, little cigars, cigarillos, cigars) receive the long-acting NRT patch; those using oral TNPs (smokeless tobacco, nicotine pouches) receive short-acting NRT gum; those using both receive the patch. Participants randomized to QuitAid who are ready to quit receive six telephonic pharmacist coaching sessions over 4 weeks; those not ready to quit receive up to three telephonic Pre-Quit Motivation Modules and may transition to QuitAid if they report readiness at any weekly check-in during Weeks 1-4. If readiness is not reported after four weekly check-ins, QuitAid ends. Follow-up assessments are conducted with all participants at 1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks via secure REDCap links or telephone. Because this is a feasibility pilot, secondary clinical outcomes are analyzed descriptively and with logistic regression only to inform a future full-scale trial.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Dylan Allanson, MPH, RD
- Número de teléfono: 4342430424
- Correo electrónico: da4ac@virginia.edu
Copia de seguridad de contactos de estudio
- Nombre: Ashley N DeMoss, MPH
- Número de teléfono: (304) 574-8073
- Correo electrónico: fzv3nn@virginia.edu
Ubicaciones de estudio
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22903
- University of Virginia
-
Sub-Investigador:
- Roger T Anderson, PhD
-
Contacto:
- Ashley N DeMoss, MPH
- Número de teléfono: (304) 574-8073
- Correo electrónico: fzv3nn@virginia.edu
-
Investigador principal:
- Melissa A Little, PhD, MPH
-
Investigador principal:
- Drew Harris, MD
-
Sub-Investigador:
- Candace H Wood, PharmD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Age ≥ 18 years
- Able to read, speak, and understand English
- A coal miner who uses tobacco and nicotine products, lives in the U.S., and has a current black-lung workers' compensation case with a participating law office
- Reports using tobacco and nicotine products daily for the past 6 months
- Willing and able to use NRT in the form of patch or gum
- Not pregnant or planning to become pregnant in the next 6 months
Exclusion Criteria:
- Medical contraindication to NRT (e.g., within the past 30 days: heart attack or stroke; within the past 6 months: serious or worsening angina, or very rapid or irregular heartbeat requiring medication)
- Pregnant or breastfeeding, or planning to become pregnant during the next 6 months
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: QuitAid + NRT
Participants receive the pharmacist-delivered QuitAid MTM program plus 24 weeks of NRT.
Those ready to quit receive six telephonic coaching sessions over 4 weeks; those not ready to quit receive up to three Pre-Quit Motivation Modules and may transition to QuitAid upon reporting readiness at a weekly check-in (Weeks 1-4).
|
Six telephonic pharmacist coaching sessions over 4 weeks focused on setting a quit date and quitting TNPs.
The first session (and subsequent proactive calls at ~days 2, 7, 14, 21, and 28) addresses negative beliefs about NRT, strengthens motivation and commitment to NRT use, monitors NRT use, provides feedback, and supports adherence.
Includes the Pre-Quit Motivation Modules (up to three telephonic sessions) for participants not yet ready to quit.
Otros nombres:
24 weeks of NRT dispensed under a standing order and mailed to participants, with standard use guidelines.
Product is matched to TNP type: long-acting patch for smoked TNP users, short-acting gum for oral TNP users, patch for dual users.
|
|
Comparador activo: NRT Only
Participants receive 24 weeks of NRT beginning in Week 1 without the QuitAid MTM program.
All follow-up assessments are conducted regardless of condition.
|
24 weeks of NRT dispensed under a standing order and mailed to participants, with standard use guidelines.
Product is matched to TNP type: long-acting patch for smoked TNP users, short-acting gum for oral TNP users, patch for dual users.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Feasibility of Randomization
Periodo de tiempo: Through study recruitment (approximately 6 months)
|
Number of coal miners who need to be approached and screened in order to randomize 100 TNP users.
|
Through study recruitment (approximately 6 months)
|
|
Retention
Periodo de tiempo: 26 weeks
|
Proportion of randomized coal miners who complete the 26-week follow-up visit.
|
26 weeks
|
|
Fidelity of Implementation
Periodo de tiempo: Through the 4-week intervention period
|
Fidelity of QuitAid delivery, assessed as adherence to QuitAid, quality of program delivery, participant responsiveness, and program differentiation, captured via a session checklist and self-reported end-of-session reflections.
|
Through the 4-week intervention period
|
|
Dose of the Medication Therapy Management (MTM) Intervention
Periodo de tiempo: Through the 4-week intervention period
|
Number of MTM (QuitAid) sessions received per participant, documented in the REDCap database.
|
Through the 4-week intervention period
|
|
Dose of NRT
Periodo de tiempo: Baseline through 26 weeks
|
Reported proportion of provided NRT that was used by participants.
|
Baseline through 26 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Self-Reported Tobacco Abstinence
Periodo de tiempo: 1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks
|
Self-reported abstinence, defined as no use of any tobacco or nicotine products within the past 7 days.
|
1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks
|
|
Quit Attempts
Periodo de tiempo: Baseline through 26 weeks
|
Number of quit attempts since the previous contact, where a quit attempt is abstinence for ≥24 hours not due to involuntary or forced cessation (e.g., hospitalization).
|
Baseline through 26 weeks
|
|
Frequency of Urges to Use TNPs
Periodo de tiempo: Baseline through 26 weeks
|
Self-reported frequency of urges to use tobacco/nicotine products.
|
Baseline through 26 weeks
|
|
Adherence to Assigned Treatment(s)
Periodo de tiempo: Baseline through 26 weeks
|
Percentage of intervention sessions completed and percentage of provided NRT used.
|
Baseline through 26 weeks
|
|
Adherence to NRT
Periodo de tiempo: Baseline through 26 weeks
|
Adherence to NRT (patch or gum), measured as the percentage of provided NRT used.
|
Baseline through 26 weeks
|
|
Strength of urges to use TNPs
Periodo de tiempo: Baseline through 26 weeks
|
Self-reported strength of urges to use tobacco/nicotine products.
|
Baseline through 26 weeks
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Program satisfaction
Periodo de tiempo: 26 weeks
|
Participant-reported barriers to treatment utilization, satisfaction with treatment components, and suggestions for improvement, with items focused on perceived capacity and opportunity to engage with the interventions.
|
26 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Melissa A Little, PhD, MPH, University of Virginia
- Investigador principal: Drew Harris, MD, University of Virginia
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Desordenes mentales
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Trastornos relacionados con sustancias
- Trastornos inducidos químicamente
- Enfermedades Pulmonares Intersticiales
- Lesión pulmonar
- Neumoconiosis
- Comportamiento
- Comportamiento de salud
- Trastorno por consumo de tabaco
- Dejar de fumar
- Dejar de consumir tabaco
- Antracosis
- Administración de Servicios de Salud
- Terapéutica
- Terapia con drogas
- Servicios de salud
- Instalaciones de atención médica Fuerza laboral y servicios
- Economía y organizaciones de la atención médica
- Gestión de atención al paciente
- Financiamiento, organizado
- Ciencias económicas
- Servicios Farmacéuticos
- Parte D de Medicare
- Seguros, Servicios Farmacéuticos
- Seguro de Salud
- Seguro
- Medicare
- Terapia de reemplazo de nicotina
- Gestión de la Terapia Medicamentosa
Otros números de identificación del estudio
- HSR 303071
- 5P30CA044579-30 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .